相关实验视频
Updated: Jun 24, 2025
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
361
在心力衰竭患者的治疗干预中准肥胖症
Ryosuke Sato1,2, Stephan von Haehling1,2
1Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.
Expert review of cardiovascular therapy
|June 12, 2024
概括
针对肥胖的药物治疗,如西马格卢提德,显示出治疗心力衰竭的前景,使用保存的喷射分数 (HFpEF). 这些治疗方法改善了肥胖HFpEF患者的结果和减少事件,突出了基于表型的方法.
科学领域:
- 心脏病学 心脏病学
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一种复杂的疾病,治疗选择有限.
- 肥胖是与HFpEF相关的显著和不断增长的表型,具有治疗目标.
- 专注于肥胖的新型干预措施正在获得HFpEF管理的关注.
研究的目的:
- 审查肥胖病原和HFpEF之间的联系.
- 探索针对HFpEF的针对肥胖的药物治疗的潜力.
- 介绍关于这种治疗策略的最新临床证据.
主要方法:
- 在PubMed进行了全面的文献搜索,截至2024年4月.
- 对临床试验数据的审查,包括STEP HFpEF和SELECT试验.
- 对类似于葡萄糖类-1 (GLP-1) 的类似物作用的分析.
主要成果:
- 作为GLP-1类型的塞马格卢提德 (Semaglutide) 对肥胖HFpEF患者的临床结果有显著的改善.
- 在SELECT试验中,semaglutide在非糖尿病肥胖个体中减少了心血管和心力衰竭事件.
- 实质性的体重减轻被认为是塞马格卢提德治疗的关键益处.
结论:
- 针对肥胖的药物治疗,特别是使用GLP-1类似物,为HFpEF提供了一个有前途的新策略.
- 基于肥胖现象型的方法对于改善HFpEF预后至关重要.
- 需要进一步研究其他隐素模拟剂和试验子分析.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:24Obesity
453
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
453